Recombinant adeno-associated virus (AAV) vectors are predominantly nonintegrating, but rare genomic integration events have been associated with oncogenesis in neonatal murine models. Here we ...
Elpida Therapeutics, a non-profit biotechnology company developing gene therapies for ultra-rare diseases, and Catalent, Inc., the leader in enabling the development and supply of better treatments ...
Notably, the AAV were designed and produced by Dan Wang, Jote Bulcha, and Guangping Gao at UMass Med. A group at Jackson Labs in Maine, including Kathy Snow, Cathleen Lutz, and Steve Murray performed ...
Oral presentation at ASGCT showcases breakthrough technology enabling precise in vivo genome editing in the CNS using a ...
Dyno Therapeutics launches two new AAV capsids and AI platform for rare disease therapeutic development at ASGCT 2026 ...
Trisk Bio Ltd, a UK-based AAV contract development and manufacturing organisation (CDMO), and NanoMosaic, Inc., a leader in advanced analytical technologies for cell and gene therapy, today announced ...
Please provide your email address to receive an email when new articles are posted on . A new simulation model can predict a range of clinical outcomes for various therapy strategies in patients with ...
U.S. Marines with 2nd Assault Amphibian Battalion (2d AABN), 2nd Marine Division (2d MARDIV), conduct an amphibious movement aboard an AAV-7A1 Assault Amphibious Vehicle during the unit's Marine Corps ...
Separating full and empty adeno-associated virus (AAV) capsids during the manufacture of single-gene therapies remains a significant challenge. Ultracentrifugation and anion exchange chromatography ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results